PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation Journal Article

Authors: Armand, P.; Chen, Y. B.; Redd, R. A.; Joyce, R. M.; Bsat, J.; Jeter, E.; Merryman, R. W.; Coleman, K. C.; Dahi, P. B.; Nieto, Y.; LaCasce, A. S.; Fisher, D. C.; Ng, S. Y.; Odejide, O. O.; Freedman, A. S.; Kim, A. I.; Crombie, J. L.; Jacobson, C. A.; Jacobsen, E. D.; Wong, J. L.; Patel, S. S.; Ritz, J.; Rodig, S. J.; Shipp, M. A.; Herrera, A. F.
Article Title: PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation
Abstract: Autologous stem cell transplantation (ASCT) remains the standard of care for patients with relapsed/refractory (RR) classical Hodgkin lymphoma (cHL) who respond to salvage chemotherapy. However, relapse after ASCT remains a frequent cause of treatment failure, with poor subsequent prognosis. Because cHL is uniquely vulnerable to programmed cell death-1 (PD-1) blockade, PD-1 blockade given as consolidation after ASCT could improve ASCT outcomes. We therefore conducted a multicohort phase 2 study of pembrolizumab in patients with RR cHL after ASCT, hypothesizing that it would improve the progression-free survival (PFS) at 18 months after ASCT (primary end point) from 60% to 80%. Pembrolizumab was administered at 200 mg IV every 3 weeks for up to 8 cycles, starting within 21 days of post-ASCT discharge. Thirty patients were treated on this study. The median age was 33 years, and 90% were high-risk by clinical criteria. Seventy-seven percent completed all 8 cycles. Toxicity was manageable, with 30% of patients experiencing at least 1 grade 3 or higher adverse event (AE), and 40% at least 1 grade 2 or higher immune-related AE. Two patients were lost to follow-up in complete remission at 12 months. The PFS at 18 months for the 28 evaluable patients was 82%, meeting the primary end point. The 18-month overall survival was 100%. In conclusion, pembrolizumab was successfully administered as post-ASCT consolidation in patients with RR cHL, and resulted in a promising PFS in a high-risk patient cohort, supporting the testing of this strategy in a randomized trial.
Keywords: expression; analysis reveals; brentuximab vedotin
Journal Title: Blood
Volume: 134
Issue: 1
ISSN: 0006-4971
Publisher: American Society of Hematology  
Date Published: 2019-07-04
Start Page: 22
End Page: 29
Language: English
ACCESSION: WOS:000474210000006
DOI: 10.1182/blood.2019000215
PMCID: PMC6609955
PUBMED: 30952672
Notes: Article -- Source: Wos
Citation Impact
MSK Authors
  1. Parastoo Bahrami Dahi
    138 Dahi